Skip to main content
. 2006 Sep 19;103(39):14453–14458. doi: 10.1073/pnas.0606512103

Fig. 3.

Fig. 3.

Specific cytotoxicity of CD8 T cell clones obtained from patient 22 (category II) and patient 19 (category III). Clones were generated by presensitization of postvaccine T cells with Ad2/ESO followed by limiting dilution and restimulation with the relevant NY-ESO-1 peptide epitope recognized after the initial stimulation. The distinct specificity of the T cell clones reflects recognition of different NY-ESO-1 epitopes (p91–110 in patient 22 and p71–90 in patient 19). Cross-reactivity against naturally processed NY-ESO-1 in tumor cells is shown by the specific reactivity against different NY-ESO-1-positive tumor cell lines (SK-Mel-52, Mel66, NW-Mel-2231) and the lack of reactivity against NY-ESO-1-negative tumor cell lines (NW-Mel-8, NW-Mel-145, SK-Mel-61) and K562. The effector-to-target cell ratio is 3:1 for patients 19 and 22.